m+Medelevator.RU
← Поиск публикаций
Chemistry (Weinheim an der Bergstrasse, Germany) · 2026

Coordination Complexes and Polymers of Novel Hybrid Tetrazole-Triazole-Pyrazole Ligands: Synthesis, Structural Characterization, and Biological Evaluation.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Bahjou Yousra, Draoui Youssef, Radi Smaail, Robeyns Koen, Li Weiyang, Miras Haralampos N, Ferbinteanu Marilena, Rotaru Aurelian, Bittner Hannah, Jakupec Michael A, Kowol Christian R, Cvetković Olivera, Wolff Mariusz, Garcia Yann

Аннотация

New series of triazole/pyrazole and tetrazole/triazole/pyrazole ligands were synthesized and coordinated with various transition metals to yield a diverse library of 14 complexes. All compounds were fully characterized by elemental analysis, mass spectrometry, powder X-ray diffractometry, and a range of spectroscopic techniques (1H NMR, 13C NMR, FT-IR, and UV-visible diffuse reflectance). The crystal and molecular structures were elucidated via single-crystal X-ray diffraction, and their supramolecular features were explored through Hirshfeld surface analysis. The 57Fe Mössbauer and magnetic SQUID measurements confirmed the high-spin nature of the FeII complex 1. In the three human cancer cell lines, most metal complexes are somewhat more cytotoxic than the inactive ligands, with Co(II) complexes 2 and 8 being the most potent in two of the cell lines (with IC50 values in the two-digit micromolar range). Overall, this study highlights how blending tetrazole/triazole/pyrazole ligands with transition metals can lead to coordination compounds with potential in anticancer research, as a proof of concept. These results add valuable insight to the expanding field of metal-based therapeutics and could help guide the development of next-generation, more effective agents.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты